Harrow (HROW) Competitors $39.30 -0.47 (-1.18%) Closing price 04:00 PM EasternExtended Trading$39.45 +0.15 (+0.38%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HROW vs. NUVL, MRUS, CRSP, TGTX, ACAD, KRYS, CYTK, MENS, ADMA, and PCVXShould you be buying Harrow stock or one of its competitors? The main competitors of Harrow include Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Cytokinetics (CYTK), Jyong Biotech (MENS), ADMA Biologics (ADMA), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Harrow vs. Its Competitors Nuvalent Merus CRISPR Therapeutics TG Therapeutics ACADIA Pharmaceuticals Krystal Biotech Cytokinetics Jyong Biotech ADMA Biologics Vaxcyte Harrow (NASDAQ:HROW) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership. Which has preferable valuation and earnings, HROW or NUVL? Harrow has higher revenue and earnings than Nuvalent. Harrow is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$199.61M7.28-$17.48M-$0.25-157.20NuvalentN/AN/A-$260.76M-$4.90-16.07 Which has more volatility and risk, HROW or NUVL? Harrow has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Do analysts prefer HROW or NUVL? Harrow currently has a consensus target price of $64.67, indicating a potential upside of 64.55%. Nuvalent has a consensus target price of $120.91, indicating a potential upside of 53.57%. Given Harrow's stronger consensus rating and higher possible upside, research analysts plainly believe Harrow is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Nuvalent 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 Is HROW or NUVL more profitable? Nuvalent has a net margin of 0.00% compared to Harrow's net margin of -4.49%. Harrow's return on equity of -2.18% beat Nuvalent's return on equity.Company Net Margins Return on Equity Return on Assets Harrow-4.49% -2.18% -0.35% Nuvalent N/A -32.58%-30.14% Do insiders & institutionals hold more shares of HROW or NUVL? 72.8% of Harrow shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 13.7% of Harrow shares are owned by insiders. Comparatively, 10.2% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer HROW or NUVL? In the previous week, Nuvalent had 8 more articles in the media than Harrow. MarketBeat recorded 16 mentions for Nuvalent and 8 mentions for Harrow. Nuvalent's average media sentiment score of 0.85 beat Harrow's score of 0.73 indicating that Nuvalent is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 7 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryHarrow beats Nuvalent on 8 of the 15 factors compared between the two stocks. Get Harrow News Delivered to You Automatically Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HROW vs. The Competition Export to ExcelMetricHarrowMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.47B$2.61B$5.81B$10.01BDividend YieldN/A49.22%5.29%4.53%P/E Ratio-157.2023.2075.6926.28Price / Sales7.28683.56538.99121.33Price / Cash290.84167.9837.2059.76Price / Book20.155.3411.506.41Net Income-$17.48M$32.95M$3.28B$270.56M7 Day Performance4.19%2.76%1.30%3.01%1 Month Performance14.14%29.32%11.25%9.74%1 Year Performance-0.05%1.14%59.54%26.68% Harrow Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HROWHarrow3.0994 of 5 stars$39.30-1.2%$64.67+64.5%+4.7%$1.47B$199.61M-157.20180NUVLNuvalent2.8763 of 5 stars$76.58+0.7%$120.80+57.7%-7.4%$5.52BN/A-15.6340News CoverageAnalyst ForecastMRUSMerus3.2007 of 5 stars$65.84-0.4%$88.75+34.8%+34.4%$4.98B$36.13M-11.9737News CoveragePositive NewsCRSPCRISPR Therapeutics3.213 of 5 stars$51.83-2.3%$71.60+38.1%+21.2%$4.71B$37.31M-9.55460Positive NewsTGTXTG Therapeutics4.298 of 5 stars$29.33+1.3%$46.25+57.7%+47.0%$4.65B$329M79.27290ACADACADIA Pharmaceuticals4.2946 of 5 stars$25.99-0.9%$28.88+11.1%+58.0%$4.38B$957.80M19.54510News CoveragePositive NewsAnalyst ForecastKRYSKrystal Biotech4.8857 of 5 stars$147.70-2.0%$210.38+42.4%-21.2%$4.27B$290.52M30.02210Positive NewsCYTKCytokinetics4.0638 of 5 stars$35.33-5.4%$71.58+102.6%-3.7%$4.23B$18.47M-6.93250MENSJyong BiotechN/A$54.81-1.3%N/AN/A$4.17BN/A0.0031ADMAADMA Biologics3.6341 of 5 stars$17.26-0.7%$27.67+60.3%+1.0%$4.12B$426.45M20.07530Positive NewsPCVXVaxcyte2.7071 of 5 stars$30.79+0.1%$136.50+343.3%-71.0%$4.00BN/A0.00160Positive News Related Companies and Tools Related Companies Nuvalent Alternatives Merus Alternatives CRISPR Therapeutics Alternatives TG Therapeutics Alternatives ACADIA Pharmaceuticals Alternatives Krystal Biotech Alternatives Cytokinetics Alternatives Jyong Biotech Alternatives ADMA Biologics Alternatives Vaxcyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HROW) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HROW Stock Alerts